News
Apo(a) size and PAD revascularisation outcomes: What’s the link?Lepodisiran: What progress towards Lp(a) reduction?Phase 1 data show sustained Lp(a) reduction with lepodisiranHeart-1 trial: Interim data show PCSK9 gene editing lowers LDL-CSmall apoA isoforms linked to worse PAD revascularisation outcomesOCEAN(a)-DOSE study highlights Lp(a) variability with time
Hot Topics
From the 19th Closed Scientific Expert Meeting of the Editorial Board
Atherogenicity of apoB-containing particles: The trilogy of LDL, Lp(a) and remnants.Professor John Chapman reviews the latest evidence.Watch now
Bempedoic acid: A CLEAR storyProfessor Steve Nissen presents CLEAR trial results showing the efficacy of bempedoic acid in statin-intolerant patients. Watch now
Slide Resource Programme
Find out more »
News from the Trials
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
- PACMAN-AMI: Sub study on alirocumab plaque effects
- SANTORINI: Supports PCSK9i combinations
- CLEAR Outcomes: Latest insights
Trial Resources
For expert analysis and insights
Most viewed
Apo(a) size and PAD revascularisation outcomes: What’s the link?
Phase 1 data show sustained Lp(a) reduction with lepodisiran
PACMAN-AMI sub study provides further insights on PCSK9i plaque effects
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?
SANTORINI data support PCSK9i combinations for high risk patients
OCEAN(a)-DOSE study highlights Lp(a) variability with time
EBBINGHAUS study reassures about cognitive safety with long-term PCSK9 inhibition
Lepodisiran: What progress towards Lp(a) reduction?
Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis
What’s new on the horizon for lipoprotein(a) therapies?
From the Editors
MK-0616 - How near is an oral PCSK9i?
Professors John Chapman and Chris Packard consider the evidence supporting MK-0616 as potentially the first oral PCSK9i to reach the clinic.
Related reports:
Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia
In Case You Missed It
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?
Aortic valve stenosis: A key pathophysiological role for Lp(a)?
Lp(a) and plaque progression: Insights from imaging
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque
News from ESC 2023
About PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.Read more »
Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis and stimulating research of novel therapeutic strategies.
JOIN TODAYMeet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the Sorbonne University
Prof Henry GinsbergIrving Professor of Medicine, Columbia University
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
